Organisation
Moderna
Country
US
mRNA vaccine
What type is it?
Interim data showed the vaccine
has an efficacy of 95%. A limited
quantity is likely to be available
in the US by the end of the year
and globally next year
When could it
be ready?
Organisation
Pfizer/ BioNTech
Country
US/Germany
mRNA vaccine
What type is it?
Interim analysis showed it was
90% effective in protecting
people from transmission. It will
probably be available in limited
quantities in the UK by the end
of the year
When could it
be ready?
Organisation
Oxford University/ AstraZeneca
Country
UK
Adenovirus vector vaccine
(delivered using a chimp
cold virus)
What type is it?
Interim results due in weeks and,
if good, limited quantities could
be available by the end of 2020
When could it
be ready?
Organisation
Novavax
Country
US
Protein adjuvant vaccine
(boosts immune system)
What type is it?
If phase 3 trials, which include
10,000 UK volunteers, go well,
there may be doses available in
the second half of next year
When could it
be ready?
Organisation
Janssen Pharmaceuticals
(part of Johnson&Johnson)
Country
US
Adenovirus vector vaccine
What type is it?
In phase 3 trials and expected
to deliver in the second half of
next year if all goes well
When could it
be ready?
Organisation
Valneva
Country
France
Traditional approach with a
whole, inactivated virus
What type is it?
Doses to be manufactured in
Scotland and available in second
half of 2021 if safety and efficacy
data is good
When could it
be ready?
Organisation
Sinovac
Country
China
Traditional approach with a
whole, inactivated virus
What type is it?
In phase 3 trials in Brazil, Indonesia and Turkey. Interim data expected in November. Trials in Brazil have resumed after one participant died by suicide. Has already been offered for emergency vaccination in the Chinese city of Jiaxing
When could it
be ready?
Organisation
Sanofi/GSK
Country
France
What type is it?
Uses the same recombinant
protein-based technology as
one of Sanofi’s seasonal flu
vaccines. GSK contributes an
adjuvant, that will be mixed
in with the vaccine to trigger
a stronger immune reaction
Phase 3 trials due to start in
December involving more than
30,000 volunteers in different
countries. Approval expected
by June 2021
When could it
be ready?
Organisation
Country
What type is it?
When could it be ready?
Moderna
US
mRNA vaccine
Interim data showed the vaccine
has an efficacy of 95%. A limited
quantity is likely to be available
in the US by the end of the year
and globally next year
Pfizer/ BioNTech
mRNA vaccine
Interim analysis showed it was
90% effective in protecting
people from transmission. It will
probably be available in limited
quantities in the UK by the end
of the year
US/Germany
Oxford University/
AstraZeneca
UK
Adenovirus vector vaccine
(it uses the virus that causes
colds in chimpanzees)
Interim results due in weeks and,
if good, limited quantities could
be available by the end of 2020
Novavax
US
Protein adjuvant vaccine
(boosts immune system)
If phase 3 trials, which include
10,000 UK volunteers, go well,
there may be doses available in
the second half of next year
Janssen Pharmaceuticals
(part of Johnson&
Johnson)
US
Adenovirus vector vaccine
In phase 3 trials and expected
to deliver in the second half of
next year if all goes well
Valneva
France
Traditional approach with a
whole, inactivated virus
Doses to be manufactured in
Scotland and available in second
half of 2021 if safety and efficacy
data is good
In phase 3 trials in Brazil, Indonesia and Turkey. Interim data expected in November. Trials in Brazil have resumed after one participant died by suicide. Has already been offered for emergency vaccination in the Chinese city of Jiaxing
Sinovac
China
Traditional approach with a
whole, inactivated virus
Sanofi/GSK
France
Uses the same recombinant
protein-based technology as
one of Sanofi’s seasonal flu
vaccines. GSK contributes an
adjuvant, that will be mixed
in with the vaccine to trigger
a stronger immune reaction
Phase 3 trials due to start in
December involving more than
30,000 volunteers in different
countries. Approval expected
by June 2021